Azafaros B.V. aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Azafaros has raised €157M across 2 funding rounds from 8 investors, most recently a Series B round in May 2025. Based in Leiden, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2025-05-14 | Series B | €132M | BioGeneration Ventures (BGV),Forbion Growth,Forbion Ventures,Jeito Capital,Pictet Group,Schroders Capital+1 more | View deal → |
| 2020-06-02 | Series A | €25M | Forbion Capital Partners | View deal → |
